Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma

Anticancer Research

Volumn 33, Issue 8, 2013, Pages 3383-3390

  Di Cristofori, Andrea ^a   Carrabba, Giorgio ^a   Lanfranchi, Giordano ^a   Menghetti, Claudia ^b   Rampini, Paolo ^a   Caroli, Manuela ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

Author keywords

Dose dense schedule; Glioblastoma; Tamoxifen; Temozolomide

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TAMOXIFEN; TEMOZOLOMIDE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DOSE DENSIFICATION; FEMALE; FOLLOW UP; GLIOBLASTOMA; GOOD GENERAL CONDITION; HUMAN; KARNOFSKY PERFORMANCE STATUS; LUMBAR SPINE; MALE; MULTIMODALITY CANCER THERAPY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT CANCER; SPINE METASTASIS; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT RESPONSE;

DOSE-DENSE SCHEDULE; GLIOBLASTOMA; TAMOXIFEN; TEMOZOLOMIDE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DACARBAZINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84883391918     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. DeAngelis LM: Brain tumors. N Engl J Med 344: 114-123, 2001.
2. Stupp R, Mason Warren P, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Panzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
3. Wick A, Pascher C, Wick W, Jauch T, Weller M, Bogdahn U and Hau P: Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol 256: 734-741, 2009.
4. Perry JR, Rizek P, Cashman R, Morrison M and Morrison T: Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule. Cancer 113(8): 2152-2157, 2008.
5. Caroli M, Locatelli M, Campanella R, Motta F, Mora A, Prada F, Borsa S, Martinelli-Boneschi F, Saladino A and Gaini SM: Temozolomide in glioblastoma: Results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol? J Neurooncol 84(1): 71-77, 2007.
6. Vertosick FT Jr., Selker RG, Pollack IF and Arena V: The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: preliminary results in a series of failed patients. Neurosurgery 30(6): 897-902, 1992.
7. Couldwell WT, Hinton DR, Surnock AA, DeGiorgio CM, Weiner LP, Apuzzo MLJ, Masri L, Law RE and Weiss MH: Treatment of recurrent malignant gliomas with chronic oral highdose tamoxifen. Clin Cancer Res 2: 619-622, 1996.
8. Muanza T, Shenouda G, Souhami L, Leblanc R, Mohr R, Corns R and Langleben A: A high-dose tamoxifen and radiotherapy in patients with glioblastoma multiforme: a phase Ib study. Can J Neurol Sci 27: 302-306, 2000.
9. Puchner MJA; Herrmann HD, Berger J and Cristante L: Surgery, tamoxifen, carboplatin, and radiotherapy in the treatment of newly diagnosed glioblastoma patients. J Neuro-Oncol 49: 147-155, 2000.
10. Spence AM, Peterson RA, Scharnhorst JD, Silbergeld DL and Rostomily RC: Phase II study of concurrent continuous temozolomide (TMZ) and tamoxifen (TMX) for recurrent malignant astrocytic gliomas. J Neuro-Oncol 70: 91-95, 2004.
11. Diaz R, Jorda MJ, Reynes G, Aparicio J, Segura A, Amador R, Calderero V and Beltran A: Neoadjuvant cisplatin and etoposide, with or without tamoxifen, prior to radiotherapy in high-grade gliomas: A single-center experience. Anticancer Drugs 16: 323-329, 2005.
12. Tang PA, Roldan G, Brasher PMA, Fulton D, Roa W, Murtha A, Cairncross JG and Forsyth PA: A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. J of Neuro-Oncol 78: 311-316, 2006.
13. Robins HI, Won M, Seiferheld WF, Schultz CJ, Choucair AK, Brachman DG, Demas WF and Mehta MP: Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-00211. Neuro Oncol 8(1): 47-52, 2006.
14. Brandes AA, Ermani M, Turazzi S, Scelzi E, Berti F, Amista P, Rotilio A, Licata C and Fiorentino MV: Procarbazine and highdose tamoxifen as a second-line regimen in recurrent high-grade gliomas: A phase II study. J of Clin Oncol 17(2): 645-650, 1999.
15. Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG and Vertosick FT Jr.: Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. Cancer Res 50: 7134-7138, 1990.
16. Puchner MJA and Giese A: Tamoxifen-resistant gliomacellsubpopulations are characterized by increased migration and proliferation. Int J Cancer 86: 468-473, 2000.
17. Baltuch GH, Couldwell WT, Villemure JG and Yong VW: Protein kinase C inhibitors suppress cell growth in established and low-passage glioma cell lines. A comparison between staurosporine and tamoxifen. Neurosurgery 33: 495-501, 1993.
18. Couldwell WT, Antel JP and Yong VW: Protein kinase C activity correlates with the growth rate of malignant gliomas: Part II: Effects of glioma mitogens and modulators of protein kinase C. Neurosurgery 31: 717-724, 1992.
19. Millward MJ, Cantwell BMJ, Lien EA, Carmichael J and Harris AL: Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance. Eur J Cancer 28: 805-810, 1992.
20. Stojkovic RR, Jovancevic M, Santel DJ, Grcevic N and Gamulin S: Sex steroid receptors in intracranial tumors. Cancer 65: 1968-1970, 1990.
21. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JEC, Hau P, Minimanoff RO, Cairncross JG, Janzer RC and Stupp R: MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. N Eng J Med 352(10): 997-1003, 2005.
22. Macdonald DR, Cascino TL, Schold SC Jr. and Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7): 1277-1280, 1990.
23. Stummer W, Meinel T, Ewelt C, Martus P, Jakobs O, Felsberg J and Reifenberger G: Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery. J Neuro-oncol 108(1): 89-97, 2012.
24. Caroli M, Beretta F, Campanella R, Locatelli M, Prada F, Farina G, Scanni A and Arienta C: Modified protocol with temozolomide in combination with tamoxifen as adjuvant chemotherapy after surgery of high grade gliomas. Neuro Oncol 4(Suppl 1): S1-S104, 2002.
25. Puchner MJA, Giese A, Lohmann F and Cristante L: High-dose tamoxifen treatment increases the incidence of multifocal tumor recurrences in glioblastoma patients. Antic Res 24: 4195-4204, 2004.
26. Raizer JJ, Grimm S, Chamberlain MC, Nicholas MK, Chandler JP, Muro K, Dubner S, Rademaker AW, Renfrow J and Bredel M: A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 15;116(22): 5297-5305, 2010.
27. Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, DeAngelis LM and Lassman AB: Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 13;73(15): 1200-1206, 2009.
28. Chamberlain MC: Radiographic patterns of relapse in glioblastoma. J Neurooncol 101(2): 319-323, 2011.
29. Patel S, DiBiase S, Meisenberg B, Flannery T, Patel A, Dhople A, Cheston S and Amin P: Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade gliomas. Int J Radiat Oncol Biol Phys 1;82(2): 739-742, 2012 (Feb).